English

Anixa Biosciences Inc

EDGAR

ANIX Quarterly report (10-Q) · filed 2026-09-09

Annual consolidated revenue for 2024: about USD 210K, using the latest reported figures. The previous period, 2023, was about USD 210K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 210000 USD Source
Revenue: 210000 USD Source

Operating cash flow

-1.97 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -6209000 USD Source
Operating Cash Flow: -4240000 USD Source

Cash and cash equivalents: 1.4 million USD 2026-07-31 Source
Exact value

1398000 USD
Long-term debt including current maturities: 370 thousand USD 2015-10-31 Source
Exact value

370181 USD
Shares outstanding: 34.6 million shares 2026-07-31 Source
Exact value

34584538 shares

Reported share-count change

5.37% · 1.76 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32822109 shares · 2025-07-31· Source
34584538 shares · 2026-07-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-10.4 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Net income: -10927000 USD · 2024-11-01 – 2025-10-31 Source
Net income: -8232000 USD · 2024-11-01 – 2025-07-31 Source
Net income: -2565000 USD · 2025-11-01 – 2026-01-31 Source
Net income: -2516000 USD · 2026-02-01 – 2026-04-30 Source
Net income: -2606000 USD · 2026-05-01 – 2026-07-31 Source

Operating cash flow

-7.38 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -7173000 USD · 2024-11-01 – 2025-10-31 Source
Operating cash flow: -5918000 USD · 2024-11-01 – 2025-07-31 Source
Operating cash flow: -2610000 USD · 2025-11-01 – 2026-01-31 Source
Operating cash flow: -4351000 USD · 2025-11-01 – 2026-04-30 Source
Operating cash flow: -2610000 USD · 2025-11-01 – 2026-01-31 Source
Operating cash flow: -6121000 USD · 2025-11-01 – 2026-07-31 Source
Operating cash flow: -4351000 USD · 2025-11-01 – 2026-04-30 Source

Capital expenditure

15.8 thousand USD

2019-11-01 – 2020-10-31

Exact inputs and evidence

Capital expenditure: 15790 USD · 2019-11-01 – 2020-01-31 Source
Capital expenditure: 15791 USD · 2019-11-01 – 2020-04-30 Source
Capital expenditure: 15790 USD · 2019-11-01 – 2020-01-31 Source
Capital expenditure: 15791 USD · 2019-11-01 – 2020-07-31 Source
Capital expenditure: 15791 USD · 2019-11-01 – 2020-04-30 Source
Capital expenditure: 15791 USD · 2019-11-01 – 2020-10-31 Source
Capital expenditure: 15791 USD · 2019-11-01 – 2020-07-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-09.

Financial data available through: 2024-10-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2024-10-31
Operating income: 11 of 11 periods available· newest 2024-10-31
Net income: 11 of 11 periods available· newest 2024-10-31
Operating cash flow: 11 of 11 periods available· newest 2024-10-31
Capital expenditure: 7 of 11 periods available· newest 2020-10-31
Total assets: 9 of 11 periods available· newest 2024-10-31
Total liabilities: 8 of 11 periods available· newest 2024-10-31
Current assets: 9 of 11 periods available· newest 2024-10-31
Current liabilities: 9 of 11 periods available· newest 2024-10-31
Cash and cash equivalents: 9 of 11 periods available· newest 2024-10-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2015-10-31
Shares outstanding: 9 of 11 periods available· newest 2024-10-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
0%

Prior period

USD 210,000

2022-11-01 – 2023-10-31
Current period

USD 210,000

2023-11-01 – 2024-10-31

Exact inputs and evidence

210000 − 210000 = 0 USD

210000 USD · 2022-11-01 – 2023-10-31
Inspect prior input Prior source
210000 USD · 2023-11-01 – 2024-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Anixa Biosciences Inc · 2024-10-31 Anixa Biosciences Inc (edgar:715446) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 210000 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#1071431 Filing: 000149315225001787 Input fundies:Revenue: 210000 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#629213 Filing: 000149315225001787
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.74 million

Prior period

−USD 9.81 million

2022-11-01 – 2023-10-31
Current period

−USD 12.55 million

2023-11-01 – 2024-10-31

Exact inputs and evidence

-12554000 − -9811000 = -2743000 USD

-9811000 USD · 2022-11-01 – 2023-10-31
Inspect prior input Prior source
-12554000 USD · 2023-11-01 – 2024-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Anixa Biosciences Inc · 2024-10-31 Anixa Biosciences Inc (edgar:715446) Year-over-year change in Net income: -2743000 USD Concept: fundies:NetIncome Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -12554000 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm#697883 Filing: 000149315226001845 Input fundies:NetIncome: -9811000 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#643712 Filing: 000149315225001787
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.13 million

Prior period

−USD 6.21 million

2022-11-01 – 2023-10-31
Current period

−USD 7.34 million

2023-11-01 – 2024-10-31

Exact inputs and evidence

-7335000 − -6209000 = -1126000 USD

-6209000 USD · 2022-11-01 – 2023-10-31
Inspect prior input Prior source
-7335000 USD · 2023-11-01 – 2024-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Anixa Biosciences Inc · 2024-10-31 Anixa Biosciences Inc (edgar:715446) Year-over-year change in Operating cash flow: -1126000 USD Concept: fundies:OperatingCashFlow Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -7335000 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm#787988 Filing: 000149315226001845 Input fundies:OperatingCashFlow: -6209000 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#737754 Filing: 000149315225001787
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2023-11-01 – 2024-10-31

Revenue USD 210,000 100% of revenue
Operating costs Derived USD 14.04 million 6,686% of revenue
Operating income −USD 13.83 million −6,586% of revenue
Tax, interest and other Derived −USD 1.28 million −608% of revenue
Net income −USD 12.55 million −5,978% of revenue

Cash

Operating cash flow −USD 7.34 million −3,493% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 110% of revenue.
2016 Operating loss: operating costs were 1,603% of revenue.
2017 Operating loss: operating costs were 1,776% of revenue.
2018 Operating loss: operating costs were 1,384% of revenue.
2019 Operating loss: operating costs were 4,856% of revenue.
2021 Operating loss: operating costs were 2,666% of revenue.
2023 Operating loss: operating costs were 5,343% of revenue.
2024 Operating loss: operating costs were 6,686% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2014-11-01 – 2015-10-31	9255000	10199759 Derived	-944759	434284 Derived	-1379043	1308591 Derived	Source 2014-11-01 – 2015-10-31: 9255000 USD Inspect Revenue Open source 2014-11-01 – 2015-10-31: -944759 USD Inspect Operating Income Open source 2014-11-01 – 2015-10-31: -1379043 USD Inspect Net Income Open source 2014-11-01 – 2015-10-31: 1363367 USD Inspect Operating Cash Flow Open source 2014-11-01 – 2015-10-31: 54776 USD Inspect Capital Expenditure Open source
2016 2015-11-01 – 2016-10-31	300000	4809012 Derived	-4509012	507416 Derived	-5016428	-3528220 Derived	Source 2015-11-01 – 2016-10-31: 300000 USD Inspect Revenue Open source 2015-11-01 – 2016-10-31: -4509012 USD Inspect Operating Income Open source 2015-11-01 – 2016-10-31: -5016428 USD Inspect Net Income Open source 2015-11-01 – 2016-10-31: -3381699 USD Inspect Operating Cash Flow Open source 2015-11-01 – 2016-10-31: 146521 USD Inspect Capital Expenditure Open source
2017 2016-11-01 – 2017-10-31	362500	6438084 Derived	-6075584	-1066593 Derived	-5008991	-3826898 Derived	Source 2016-11-01 – 2017-10-31: 362500 USD Inspect Revenue Open source 2016-11-01 – 2017-10-31: -6075584 USD Inspect Operating Income Open source 2016-11-01 – 2017-10-31: -5008991 USD Inspect Net Income Open source 2016-11-01 – 2017-10-31: -3796710 USD Inspect Operating Cash Flow Open source 2016-11-01 – 2017-10-31: 30188 USD Inspect Capital Expenditure Open source
2018 2017-11-01 – 2018-10-31	1112500	15401558 Derived	-14289058	-293033 Derived	-13996025	-4311804 Derived	Source 2017-11-01 – 2018-10-31: 1112500 USD Inspect Revenue Open source 2017-11-01 – 2018-10-31: -14289058 USD Inspect Operating Income Open source 2017-11-01 – 2018-10-31: -13996025 USD Inspect Net Income Open source 2017-11-01 – 2018-10-31: -4273400 USD Inspect Operating Cash Flow Open source 2017-11-01 – 2018-10-31: 38404 USD Inspect Capital Expenditure Open source
2019 2018-11-01 – 2019-10-31	250000	12140005 Derived	-11890005	-242951 Derived	-11647054	-4916883 Derived	Source 2018-11-01 – 2019-10-31: 250000 USD Inspect Revenue Open source 2018-11-01 – 2019-10-31: -11890005 USD Inspect Operating Income Open source 2018-11-01 – 2019-10-31: -11647054 USD Inspect Net Income Open source 2018-11-01 – 2019-10-31: -4741426 USD Inspect Operating Cash Flow Open source 2018-11-01 – 2019-10-31: 175457 USD Inspect Capital Expenditure Open source
2021 2020-11-01 – 2021-10-31	512000	13648000 Derived	-13136000	-182000 Derived	-12954000	Unavailable	Source 2020-11-01 – 2021-10-31: 512000 USD Inspect Revenue Open source 2020-11-01 – 2021-10-31: -13136000 USD Inspect Operating Income Open source 2020-11-01 – 2021-10-31: -12954000 USD Inspect Net Income Open source 2020-11-01 – 2021-10-31: -4938000 USD Inspect Operating Cash Flow Open source
2023 2022-11-01 – 2023-10-31	210000	11221000 Derived	-11011000	-1200000 Derived	-9811000	Unavailable	Source 2022-11-01 – 2023-10-31: 210000 USD Inspect Revenue Open source 2022-11-01 – 2023-10-31: -11011000 USD Inspect Operating Income Open source 2022-11-01 – 2023-10-31: -9811000 USD Inspect Net Income Open source 2022-11-01 – 2023-10-31: -6209000 USD Inspect Operating Cash Flow Open source
2024 2023-11-01 – 2024-10-31	210000	14041000 Derived	-13831000	-1277000 Derived	-12554000	Unavailable	Source 2023-11-01 – 2024-10-31: 210000 USD Inspect Revenue Open source 2023-11-01 – 2024-10-31: -13831000 USD Inspect Operating Income Open source 2023-11-01 – 2024-10-31: -12554000 USD Inspect Net Income Open source 2023-11-01 – 2024-10-31: -7335000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 210K 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-10-31	Revenue	3667320	Revenue: 3667320 Open source
20152015-10-31	Revenue	9255000	Revenue: 9255000 Open source
20162016-10-31	Revenue	300000	Revenue: 300000 Open source
20172017-10-31	Revenue	362500	Revenue: 362500 Open source
20182018-10-31	Revenue	1112500	Revenue: 1112500 Open source
20192019-10-31	Revenue	250000	Revenue: 250000 Open source
20212021-10-31	Revenue	512000	Revenue: 512000 Open source
20232023-10-31	Revenue	210000	Revenue: 210000 Open source
20242024-10-31	Revenue	210000	Revenue: 210000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

0% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-10-31	Year over year	No prior comparable period	Revenue: 3667320 Open source
20152015-10-31	Year over year	152.4%	Revenue: 9255000 Open source Revenue: 3667320 Open source
20162016-10-31	Year over year	-96.8%	Revenue: 300000 Open source Revenue: 9255000 Open source
20172017-10-31	Year over year	20.8%	Revenue: 362500 Open source Revenue: 300000 Open source
20182018-10-31	Year over year	206.9%	Revenue: 1112500 Open source Revenue: 362500 Open source
20192019-10-31	Year over year	-77.5%	Revenue: 250000 Open source Revenue: 1112500 Open source
20212021-10-31	Year over year	No prior comparable period	Revenue: 512000 Open source
20232023-10-31	Year over year	No prior comparable period	Revenue: 210000 Open source
20242024-10-31	Year over year	0%	Revenue: 210000 Open source Revenue: 210000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -6,586.2% 2024

Net margin -5,978.1% 2024

Free cash flow margin -1,966.8% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-10-31	Operating margin	-137.5%	Operating Income: -5044068 Open source Revenue: 3667320 Open source
20152015-10-31	Operating margin	-10.2%	Operating Income: -944759 Open source Revenue: 9255000 Open source
20162016-10-31	Operating margin	-1,503%	Operating Income: -4509012 Open source Revenue: 300000 Open source
20172017-10-31	Operating margin	-1,676%	Operating Income: -6075584 Open source Revenue: 362500 Open source
20182018-10-31	Operating margin	-1,284.4%	Operating Income: -14289058 Open source Revenue: 1112500 Open source
20192019-10-31	Operating margin	-4,756%	Operating Income: -11890005 Open source Revenue: 250000 Open source
20212021-10-31	Operating margin	-2,565.6%	Operating Income: -13136000 Open source Revenue: 512000 Open source
20232023-10-31	Operating margin	-5,243.3%	Operating Income: -11011000 Open source Revenue: 210000 Open source
20242024-10-31	Operating margin	-6,586.2%	Operating Income: -13831000 Open source Revenue: 210000 Open source
20142014-10-31	Net margin	-261.9%	Net Income: -9606314 Open source Revenue: 3667320 Open source
20152015-10-31	Net margin	-14.9%	Net Income: -1379043 Open source Revenue: 9255000 Open source
20162016-10-31	Net margin	-1,672.1%	Net Income: -5016428 Open source Revenue: 300000 Open source
20172017-10-31	Net margin	-1,381.8%	Net Income: -5008991 Open source Revenue: 362500 Open source
20182018-10-31	Net margin	-1,258.1%	Net Income: -13996025 Open source Revenue: 1112500 Open source
20192019-10-31	Net margin	-4,658.8%	Net Income: -11647054 Open source Revenue: 250000 Open source
20212021-10-31	Net margin	-2,530.1%	Net Income: -12954000 Open source Revenue: 512000 Open source
20232023-10-31	Net margin	-4,671.9%	Net Income: -9811000 Open source Revenue: 210000 Open source
20242024-10-31	Net margin	-5,978.1%	Net Income: -12554000 Open source Revenue: 210000 Open source
20142014-10-31	Free cash flow margin	Not reported	Revenue: 3667320 Open source
20152015-10-31	Free cash flow margin	14.1%	Revenue: 9255000 Open source Operating Cash Flow: 1363367 Open source Capital Expenditure: 54776 Open source
20162016-10-31	Free cash flow margin	-1,176.1%	Revenue: 300000 Open source Operating Cash Flow: -3381699 Open source Capital Expenditure: 146521 Open source
20172017-10-31	Free cash flow margin	-1,055.7%	Revenue: 362500 Open source Operating Cash Flow: -3796710 Open source Capital Expenditure: 30188 Open source
20182018-10-31	Free cash flow margin	-387.6%	Revenue: 1112500 Open source Operating Cash Flow: -4273400 Open source Capital Expenditure: 38404 Open source
20192019-10-31	Free cash flow margin	-1,966.8%	Revenue: 250000 Open source Operating Cash Flow: -4741426 Open source Capital Expenditure: 175457 Open source
20212021-10-31	Free cash flow margin	Not reported	Revenue: 512000 Open source Operating Cash Flow: -4938000 Open source
20232023-10-31	Free cash flow margin	Not reported	Revenue: 210000 Open source Operating Cash Flow: -6209000 Open source
20242024-10-31	Free cash flow margin	Not reported	Revenue: 210000 Open source Operating Cash Flow: -7335000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -7.3M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-10-31	Operating cash flow	Not reported	No source recorded
20152015-10-31	Operating cash flow	1363367	Operating Cash Flow: 1363367 Open source
20162016-10-31	Operating cash flow	-3381699	Operating Cash Flow: -3381699 Open source
20172017-10-31	Operating cash flow	-3796710	Operating Cash Flow: -3796710 Open source
20182018-10-31	Operating cash flow	-4273400	Operating Cash Flow: -4273400 Open source
20192019-10-31	Operating cash flow	-4741426	Operating Cash Flow: -4741426 Open source
20212021-10-31	Operating cash flow	-4938000	Operating Cash Flow: -4938000 Open source
20232023-10-31	Operating cash flow	-6209000	Operating Cash Flow: -6209000 Open source
20242024-10-31	Operating cash flow	-7335000	Operating Cash Flow: -7335000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -4.9M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-10-31	Free cash flow	Unavailable	No source recorded
20152015-10-31	Free cash flow	1308591	Operating Cash Flow: 1363367 Open source Capital Expenditure: 54776 Open source
20162016-10-31	Free cash flow	-3528220	Operating Cash Flow: -3381699 Open source Capital Expenditure: 146521 Open source
20172017-10-31	Free cash flow	-3826898	Operating Cash Flow: -3796710 Open source Capital Expenditure: 30188 Open source
20182018-10-31	Free cash flow	-4311804	Operating Cash Flow: -4273400 Open source Capital Expenditure: 38404 Open source
20192019-10-31	Free cash flow	-4916883	Operating Cash Flow: -4741426 Open source Capital Expenditure: 175457 Open source
20212021-10-31	Free cash flow	Unavailable	Operating Cash Flow: -4938000 Open source
20232023-10-31	Free cash flow	Unavailable	Operating Cash Flow: -6209000 Open source
20242024-10-31	Free cash flow	Unavailable	Operating Cash Flow: -7335000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12.5% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-10-31	Liabilities / assets	55.7%	Total Liabilities: 5045783 Open source Total Assets: 9055356 Open source
20152015-10-31	Liabilities / assets	45.9%	Total Liabilities: 4281969 Open source Total Assets: 9335570 Open source
20162016-10-31	Liabilities / assets	82.5%	Total Liabilities: 4640632 Open source Total Assets: 5628107 Open source
20172017-10-31	Liabilities / assets	10.1%	Total Liabilities: 889493 Open source Total Assets: 8812416 Open source
2018-10-31	Liabilities / assets	Not reported	Total Assets: 6448542 Open source
20192019-10-31	Liabilities / assets	23.5%	Total Liabilities: 1481315 Open source Total Assets: 6293693 Open source
20212021-10-31	Liabilities / assets	4.1%	Total Liabilities: 1490000 Open source Total Assets: 36257000 Open source
20232023-10-31	Liabilities / assets	8.4%	Total Liabilities: 2151000 Open source Total Assets: 25522000 Open source
20242024-10-31	Liabilities / assets	12.5%	Total Liabilities: 2703000 Open source Total Assets: 21591000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.54× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-10-31	Current assets / current liabilities	3.49×	Current Assets: 6321823 Open source Current Liabilities: 1809502 Open source
20152015-10-31	Current assets / current liabilities	11.61×	Current Assets: 6895747 Open source Current Liabilities: 593782 Open source
20162016-10-31	Current assets / current liabilities	7.25×	Current Assets: 3400392 Open source Current Liabilities: 468756 Open source
20172017-10-31	Current assets / current liabilities	7.89×	Current Assets: 7013940 Open source Current Liabilities: 889493 Open source
20182018-10-31	Current assets / current liabilities	4.38×	Current Assets: 5538372 Open source Current Liabilities: 1265111 Open source
20192019-10-31	Current assets / current liabilities	4.11×	Current Assets: 6093124 Open source Current Liabilities: 1481315 Open source
20212021-10-31	Current assets / current liabilities	28.35×	Current Assets: 36003000 Open source Current Liabilities: 1270000 Open source
20232023-10-31	Current assets / current liabilities	12.5×	Current Assets: 25356000 Open source Current Liabilities: 2028000 Open source
20242024-10-31	Current assets / current liabilities	8.54×	Current Assets: 21362000 Open source Current Liabilities: 2500000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2014-11-01 – 2015-10-31	−USD 1.38 million Exact value Exact value: -1379043 USD 2014-11-01 – 2015-10-31: -1379043 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2015-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -1379043 USD Concept: fundies:NetIncome Period: 2014-11-01 to 2015-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2015-10-31&surface=latest&period_type=duration&start=2014-11-01&unit=USD&dimensions= Input fundies:NetIncome: -1379043 USD (2014-11-01 to 2015-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316217000027/itus-20161031.xml#89338 Filing: 000151316217000027 The citation records this snapshot. The page link may show a newer release later.	USD 1.36 million Exact value Exact value: 1363367 USD 2014-11-01 – 2015-10-31: 1363367 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2015-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: 1363367 USD Concept: fundies:OperatingCashFlow Period: 2014-11-01 to 2015-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2015-10-31&surface=latest&period_type=duration&start=2014-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1363367 USD (2014-11-01 to 2015-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316217000027/itus-20161031.xml#104580 Filing: 000151316217000027 The citation records this snapshot. The page link may show a newer release later.	USD 54,776 Exact value Exact value: 54776 USD 2014-11-01 – 2015-10-31: 54776 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2015-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 54776 USD Concept: fundies:CapitalExpenditure Period: 2014-11-01 to 2015-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2015-10-31&surface=latest&period_type=duration&start=2014-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 54776 USD (2014-11-01 to 2015-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316217000027/itus-20161031.xml#105635 Filing: 000151316217000027 The citation records this snapshot. The page link may show a newer release later.	USD 1.31 million Calculation and evidence 1363367 − 54776 USD Exact free cash flow: 1308591 USD 2014-11-01 – 2015-10-31: 1363367 USD · Inspect Operating Cash Flow · Source 2014-11-01 – 2015-10-31: 54776 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2015-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: 1308591 USD Concept: free-cash-flow Period: 2014-11-01 to 2015-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1363367 USD (2014-11-01 to 2015-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316217000027/itus-20161031.xml#104580 Filing: 000151316217000027 Input fundies:CapitalExpenditure: 54776 USD (2014-11-01 to 2015-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316217000027/itus-20161031.xml#105635 Filing: 000151316217000027 The citation records this snapshot. The page link may show a newer release later.
2016 2015-11-01 – 2016-10-31	−USD 5.02 million Exact value Exact value: -5016428 USD 2015-11-01 – 2016-10-31: -5016428 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2016-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -5016428 USD Concept: fundies:NetIncome Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:NetIncome: -5016428 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316218000006/itus-20171031.xml#79143 Filing: 000151316218000006 The citation records this snapshot. The page link may show a newer release later.	−USD 3.38 million Exact value Exact value: -3381699 USD 2015-11-01 – 2016-10-31: -3381699 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2016-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -3381699 USD Concept: fundies:OperatingCashFlow Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3381699 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316218000006/itus-20171031.xml#96654 Filing: 000151316218000006 The citation records this snapshot. The page link may show a newer release later.	USD 146,521 Exact value Exact value: 146521 USD 2015-11-01 – 2016-10-31: 146521 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2016-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 146521 USD Concept: fundies:CapitalExpenditure Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 146521 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316218000006/itus-20171031.xml#98016 Filing: 000151316218000006 The citation records this snapshot. The page link may show a newer release later.	−USD 3.53 million Calculation and evidence -3381699 − 146521 USD Exact free cash flow: -3528220 USD 2015-11-01 – 2016-10-31: -3381699 USD · Inspect Operating Cash Flow · Source 2015-11-01 – 2016-10-31: 146521 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2016-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: -3528220 USD Concept: free-cash-flow Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3381699 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316218000006/itus-20171031.xml#96654 Filing: 000151316218000006 Input fundies:CapitalExpenditure: 146521 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316218000006/itus-20171031.xml#98016 Filing: 000151316218000006 The citation records this snapshot. The page link may show a newer release later.
2017 2016-11-01 – 2017-10-31	−USD 5.01 million Exact value Exact value: -5008991 USD 2016-11-01 – 2017-10-31: -5008991 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2017-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -5008991 USD Concept: fundies:NetIncome Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:NetIncome: -5008991 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#101040 Filing: 000151316219000016 The citation records this snapshot. The page link may show a newer release later.	−USD 3.8 million Exact value Exact value: -3796710 USD 2016-11-01 – 2017-10-31: -3796710 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2017-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -3796710 USD Concept: fundies:OperatingCashFlow Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3796710 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#129791 Filing: 000151316219000016 The citation records this snapshot. The page link may show a newer release later.	USD 30,188 Exact value Exact value: 30188 USD 2016-11-01 – 2017-10-31: 30188 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2017-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 30188 USD Concept: fundies:CapitalExpenditure Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 30188 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#131153 Filing: 000151316219000016 The citation records this snapshot. The page link may show a newer release later.	−USD 3.83 million Calculation and evidence -3796710 − 30188 USD Exact free cash flow: -3826898 USD 2016-11-01 – 2017-10-31: -3796710 USD · Inspect Operating Cash Flow · Source 2016-11-01 – 2017-10-31: 30188 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2017-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: -3826898 USD Concept: free-cash-flow Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3796710 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#129791 Filing: 000151316219000016 Input fundies:CapitalExpenditure: 30188 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#131153 Filing: 000151316219000016 The citation records this snapshot. The page link may show a newer release later.
2018 2017-11-01 – 2018-10-31	−USD 14 million Exact value Exact value: -13996025 USD 2017-11-01 – 2018-10-31: -13996025 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2018-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -13996025 USD Concept: fundies:NetIncome Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:NetIncome: -13996025 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316219000016/anix-20181031.xml#100914 Filing: 000151316219000016 The citation records this snapshot. The page link may show a newer release later.	−USD 4.27 million Exact value Exact value: -4273400 USD 2017-11-01 – 2018-10-31: -4273400 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2018-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -4273400 USD Concept: fundies:OperatingCashFlow Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4273400 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316220000009/anix-20191031.xml#130746 Filing: 000151316220000009 The citation records this snapshot. The page link may show a newer release later.	USD 38,404 Exact value Exact value: 38404 USD 2017-11-01 – 2018-10-31: 38404 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2018-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 38404 USD Concept: fundies:CapitalExpenditure Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 38404 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316220000009/anix-20191031.xml#131814 Filing: 000151316220000009 The citation records this snapshot. The page link may show a newer release later.	−USD 4.31 million Calculation and evidence -4273400 − 38404 USD Exact free cash flow: -4311804 USD 2017-11-01 – 2018-10-31: -4273400 USD · Inspect Operating Cash Flow · Source 2017-11-01 – 2018-10-31: 38404 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2018-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: -4311804 USD Concept: free-cash-flow Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4273400 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316220000009/anix-20191031.xml#130746 Filing: 000151316220000009 Input fundies:CapitalExpenditure: 38404 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000151316220000009/anix-20191031.xml#131814 Filing: 000151316220000009 The citation records this snapshot. The page link may show a newer release later.
2019 2018-11-01 – 2019-10-31	−USD 11.65 million Exact value Exact value: -11647054 USD 2018-11-01 – 2019-10-31: -11647054 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2019-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -11647054 USD Concept: fundies:NetIncome Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:NetIncome: -11647054 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315221000456/anix-20201031.xml#126814 Filing: 000149315221000456 The citation records this snapshot. The page link may show a newer release later.	−USD 4.74 million Exact value Exact value: -4741426 USD 2018-11-01 – 2019-10-31: -4741426 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2019-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -4741426 USD Concept: fundies:OperatingCashFlow Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4741426 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315221000456/anix-20201031.xml#152519 Filing: 000149315221000456 The citation records this snapshot. The page link may show a newer release later.	USD 175,457 Exact value Exact value: 175457 USD 2018-11-01 – 2019-10-31: 175457 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2019-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 175457 USD Concept: fundies:CapitalExpenditure Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 175457 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315221000456/anix-20201031.xml#187610 Filing: 000149315221000456 The citation records this snapshot. The page link may show a newer release later.	−USD 4.92 million Calculation and evidence -4741426 − 175457 USD Exact free cash flow: -4916883 USD 2018-11-01 – 2019-10-31: -4741426 USD · Inspect Operating Cash Flow · Source 2018-11-01 – 2019-10-31: 175457 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2019-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: -4916883 USD Concept: free-cash-flow Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4741426 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315221000456/anix-20201031.xml#152519 Filing: 000149315221000456 Input fundies:CapitalExpenditure: 175457 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315221000456/anix-20201031.xml#187610 Filing: 000149315221000456 The citation records this snapshot. The page link may show a newer release later.
2020 2019-11-01 – 2020-10-31	−USD 10.02 million Exact value Exact value: -10018355 USD 2019-11-01 – 2020-10-31: -10018355 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2020-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -10018355 USD Concept: fundies:NetIncome Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:NetIncome: -10018355 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315222000302/form10-k.htm#790945 Filing: 000149315222000302 The citation records this snapshot. The page link may show a newer release later.	−USD 6.18 million Exact value Exact value: -6175671 USD 2019-11-01 – 2020-10-31: -6175671 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2020-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -6175671 USD Concept: fundies:OperatingCashFlow Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6175671 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315222000302/form10-k.htm#1016812 Filing: 000149315222000302 The citation records this snapshot. The page link may show a newer release later.	USD 15,791 Exact value Exact value: 15791 USD 2019-11-01 – 2020-10-31: 15791 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Anixa Biosciences Inc · 2020-10-31 Anixa Biosciences Inc (edgar:715446) Capital Expenditure: 15791 USD Concept: fundies:CapitalExpenditure Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ACapitalExpenditure&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15791 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315222000302/form10-k.htm#1030315 Filing: 000149315222000302 The citation records this snapshot. The page link may show a newer release later.	−USD 6.19 million Calculation and evidence -6175671 − 15791 USD Exact free cash flow: -6191462 USD 2019-11-01 – 2020-10-31: -6175671 USD · Inspect Operating Cash Flow · Source 2019-11-01 – 2020-10-31: 15791 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Anixa Biosciences Inc · 2020-10-31 Anixa Biosciences Inc (edgar:715446) Free cash flow: -6191462 USD Concept: free-cash-flow Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6175671 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315222000302/form10-k.htm#1016812 Filing: 000149315222000302 Input fundies:CapitalExpenditure: 15791 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315222000302/form10-k.htm#1030315 Filing: 000149315222000302 The citation records this snapshot. The page link may show a newer release later.
2021 2020-11-01 – 2021-10-31	−USD 12.95 million Exact value Exact value: -12954000 USD 2020-11-01 – 2021-10-31: -12954000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2021-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -12954000 USD Concept: fundies:NetIncome Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2021-10-31&surface=latest&period_type=duration&start=2020-11-01&unit=USD&dimensions= Input fundies:NetIncome: -12954000 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315223000346/form10-k.htm#680672 Filing: 000149315223000346 The citation records this snapshot. The page link may show a newer release later.	−USD 4.94 million Exact value Exact value: -4938000 USD 2020-11-01 – 2021-10-31: -4938000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2021-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -4938000 USD Concept: fundies:OperatingCashFlow Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2021-10-31&surface=latest&period_type=duration&start=2020-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4938000 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315223000346/form10-k.htm#768674 Filing: 000149315223000346 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2021-11-01 – 2022-10-31	−USD 13.6 million Exact value Exact value: -13595000 USD 2021-11-01 – 2022-10-31: -13595000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2022-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -13595000 USD Concept: fundies:NetIncome Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2022-10-31&surface=latest&period_type=duration&start=2021-11-01&unit=USD&dimensions= Input fundies:NetIncome: -13595000 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315224002453/form10-k.htm#704664 Filing: 000149315224002453 The citation records this snapshot. The page link may show a newer release later.	−USD 6.49 million Exact value Exact value: -6492000 USD 2021-11-01 – 2022-10-31: -6492000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2022-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -6492000 USD Concept: fundies:OperatingCashFlow Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2022-10-31&surface=latest&period_type=duration&start=2021-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6492000 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315224002453/form10-k.htm#883422 Filing: 000149315224002453 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2022-11-01 – 2023-10-31	−USD 9.81 million Exact value Exact value: -9811000 USD 2022-11-01 – 2023-10-31: -9811000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2023-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -9811000 USD Concept: fundies:NetIncome Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2023-10-31&surface=latest&period_type=duration&start=2022-11-01&unit=USD&dimensions= Input fundies:NetIncome: -9811000 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#643712 Filing: 000149315225001787 The citation records this snapshot. The page link may show a newer release later.	−USD 6.21 million Exact value Exact value: -6209000 USD 2022-11-01 – 2023-10-31: -6209000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2023-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -6209000 USD Concept: fundies:OperatingCashFlow Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2023-10-31&surface=latest&period_type=duration&start=2022-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6209000 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/form10-k.htm#737754 Filing: 000149315225001787 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2023-11-01 – 2024-10-31	−USD 12.55 million Exact value Exact value: -12554000 USD 2023-11-01 – 2024-10-31: -12554000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Anixa Biosciences Inc · 2024-10-31 Anixa Biosciences Inc (edgar:715446) Net Income: -12554000 USD Concept: fundies:NetIncome Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3ANetIncome&period=2024-10-31&surface=latest&period_type=duration&start=2023-11-01&unit=USD&dimensions= Input fundies:NetIncome: -12554000 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm#697883 Filing: 000149315226001845 The citation records this snapshot. The page link may show a newer release later.	−USD 7.34 million Exact value Exact value: -7335000 USD 2023-11-01 – 2024-10-31: -7335000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Anixa Biosciences Inc · 2024-10-31 Anixa Biosciences Inc (edgar:715446) Operating Cash Flow: -7335000 USD Concept: fundies:OperatingCashFlow Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T23:01:20Z Snapshot: d6ac35dd44a8da9fa91650938e3c0dc371af5573782b7a87972fd297fed1f56b Dimensions: Consolidated View: https://fundies.io/companies/edgar/715446/explain?concept=fundies%3AOperatingCashFlow&period=2024-10-31&surface=latest&period_type=duration&start=2023-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7335000 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm#787988 Filing: 000149315226001845 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

211 filings · 3,661 latest values · 3,661 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000715446, 715446, ANIX, edgar:715446

Also known as ANIXA BIOSCIENCES, INC., ANIXA BIOSCIENCES, INC., ANIXA BIOSCIENCES, INC., Anixa Biosciences Inc, Anixa Biosciences, Inc., COPYTELE INC, ITUS CORPORATION, ITUS Corp

Anixa Biosciences Inc

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2024 2023-11-01 – 2024-10-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation